Barkby Group Plc. has completed a successful reverse takeover, placing and subscription
The management team of Barkby Group Plc. has completed a reverse takeover of Tarncourt Ambit Properties Limited, Tarncourt Ambit Limited and Workshop Trading Holdings Limited.
Barkby Group is built on a diverse portfolio of businesses within evolving markets. It comprises three separate divisions: life sciences, real estate and consumer and hospitality. Life sciences includes Cambridge Sleep Sciences, which has rights to the exclusive design and production of the SleepHub™ device to improve and facilitate natural sleep, and Vivoplex, a digital health company aiming to transform fertility treatments with precision medicine. The group’s commercial property development specializes in developing contract-backed sites in the southeast of England. The company has a proven profitable track record of sourcing and developing commercial property projects. The consumer and hospitality portfolio is comprised of three separate growth businesses: Workshop Coffee, Barkby Pubs and Centurian Automotive.
During this process, Oaklins Cavendish’s sister firm finnCap, based in the UK, initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, deal structuring, and the reverse pricing and sizing.
Talk to the deal team
Related deals
Hemink Groep has been acquired by Gimv
Gimv has acquired a majority stake in Hemink, a Dutch specialist in real estate renovation and maintenance. This transaction marks a new chapter for Hemink, as it seeks to expand its position as a national leader in sustainable property services through its new partnership with Gimv.
Learn moreSt. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn moreA share exchange agreement for making NARUMIYA a wholly owned subsidiary of World has been executed
World Co., Ltd. and NARUMIYA INTERNATIONAL Co., Ltd. have entered into a definitive share exchange agreement, under which World will acquire all outstanding shares of NARUMIYA and make it a wholly owned subsidiary. The share exchange is scheduled to take effect on 1 October 2025. Under the terms of the agreement, NARUMIYA shareholders will receive 0.58 shares of World stock for each Narumiya share they hold.
Learn more